ReviewJournal of nanobiotechnology2025
Copper-based metal-organic frameworks for antitumor application.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Copper-based metal-organic frameworks: applications and prospects in cancer diagnosis and therapy.RSC advances · 2026Review
- Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities.Journal of hematology & oncology · 2026Review
- Copper Complexes: Emerging Micro- and Nanosystems for Dermatological Treatment.Pharmaceutics · 2026Review
- Mechanisms and Applications of Manganese-Based Materials in Tumor Immunotherapy.Molecules (Basel, Switzerland) · 2026Review
- Therapeutic horizons of cuproptosis: bibliometric mapping of copper-dependent cell death research and its pharmacological implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Tumor lysate-cloaked CuMOF-sorafenib nanoassembler: A synergistic cuproptosis-ferroptosis nanoweapon against tumors.Materials today. Bio · 2026Article
- Therapeutic Metal Ions: Engineering Biomaterials for Multimodal Disease Treatment.International journal of nanomedicine · 2026Review
- Nanodynamic Therapy in Colorectal Cancer: Engineering Precision Immunotherapy and Multimodal Synergy.International journal of nanomedicine · 2026Review
- Polyphenol-Based Functional Materials: Structural Insights, Composite Strategies, and Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nanoscale metal-organic frameworks as a versatile platform for synergistic combination tumor therapy.Journal of nanobiotechnology · 2025Review
- A Review on the Design Strategies of Copper-Based Catalysts for Enhanced Activity and Stability in Methanol Reforming to Hydrogen.Nanomaterials (Basel, Switzerland) · 2025Review
- Advances in Photothermal Electrospinning: From Fiber Fabrication to Biomedical Application.Polymers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
It is urgent to exploit multifunctional materials and combined approaches for efficient antitumor effects. Copper-based metal-organic frameworks (Cu-MOFs) have excellent performances in catalysis, biocompatibility, photothermal conversion, and regulate metabolism, which make them attract more and more attention in antitumor application. Therefore, in this review, representative ligands, synthetic methods, antitumor mechanism, and antitumor applications of Cu-MOFs were provided. Special emphasis is placed on the recent antitumor applications of Cu-MOFs in drug carriers, antitumor therapy, tumor imaging, and theranostic, which are summarized with examples. Finally, we presented the dilemma faced by Cu-MOFs and offered a new perspective for future antitumor application. Hopefully, this review may serve as a reference for further development and application of Cu-MOFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.